U.K's Heptares Signs Up AstraZeneca In Latest GPCR-Focused Discovery Pact
This article was originally published in The Pink Sheet Daily
AstraZeneca becomes the third Big Pharma in six weeks to sign up for U.K-based Heptares' GPCR stabilizing technology.
You may also be interested in...
This past week saw two GPCR-focused deals – Shire’s optioning of a preclinical adenosine A2a antagonist and Anaphore’s acquisition of a platform company specializing in biologics targeting GPCRs.
The U.K.'s G-protein coupled receptor specialist, Heptares, could receive up to $190 million plus royalties from Shire as it concludes its first product out-licensing agreement.
AstraZeneca isn't the first to attempt to reinvigorate its R&D organization. But the group's pure-pharma focus means it relies more heavily than most of its peers on the success of this organizational and cultural overhaul.